266 related articles for article (PubMed ID: 25085429)
1. Evaluation of a head-to-head study of lisdexamfetamine dimesylate and atomoxetine: evaluation of Dittmann RW, Cardo E, Nagy P, et al. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomised, double-blind, Phase IIIb study. CNS Drugs 2013;27:1081-1092. doi: 10.1007/s40263-013-0104-8 ClinicalTrials.gov: NCT01106430.
Banaschewski T; Rothermel B; Poustka L
Expert Opin Pharmacother; 2014 Sep; 15(13):1961-5. PubMed ID: 25085429
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.
Dittmann RW; Cardo E; Nagy P; Anderson CS; Bloomfield R; Caballero B; Higgins N; Hodgkins P; Lyne A; Civil R; Coghill D
CNS Drugs; 2013 Dec; 27(12):1081-92. PubMed ID: 23959815
[TBL] [Abstract][Full Text] [Related]
3. Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.
Dittmann RW; Cardo E; Nagy P; Anderson CS; Adeyi B; Caballero B; Hodgkins P; Civil R; Coghill DR
CNS Drugs; 2014 Nov; 28(11):1059-69. PubMed ID: 25038977
[TBL] [Abstract][Full Text] [Related]
4. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
[TBL] [Abstract][Full Text] [Related]
5. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
[TBL] [Abstract][Full Text] [Related]
6. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
[TBL] [Abstract][Full Text] [Related]
7. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
King S; Griffin S; Hodges Z; Weatherly H; Asseburg C; Richardson G; Golder S; Taylor E; Drummond M; Riemsma R
Health Technol Assess; 2006 Jul; 10(23):iii-iv, xiii-146. PubMed ID: 16796929
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion.
Stuhec M; Munda B; Svab V; Locatelli I
J Affect Disord; 2015 Jun; 178():149-59. PubMed ID: 25813457
[TBL] [Abstract][Full Text] [Related]
9. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
Coghill D; Banaschewski T; Lecendreux M; Soutullo C; Johnson M; Zuddas A; Anderson C; Civil R; Higgins N; Lyne A; Squires L
Eur Neuropsychopharmacol; 2013 Oct; 23(10):1208-18. PubMed ID: 23332456
[TBL] [Abstract][Full Text] [Related]
10. Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder.
Najib J; Didenko E; Meleshkina D; Yusupov K; Maw K; Ramnarain J; Tabassum M
Curr Med Res Opin; 2020 Oct; 36(10):1717-1735. PubMed ID: 32845786
[TBL] [Abstract][Full Text] [Related]
11. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
May DE; Kratochvil CJ
Drugs; 2010; 70(1):15-40. PubMed ID: 20030423
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder and recent methylphenidate use.
Jain R; Babcock T; Burtea T; Dirks B; Adeyi B; Scheckner B; Lasser R; Renna J; Duncan D
Adv Ther; 2013 May; 30(5):472-86. PubMed ID: 23681505
[TBL] [Abstract][Full Text] [Related]
13. A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.
Zimovetz EA; Joseph A; Ayyagari R; Mauskopf JA
Eur J Health Econ; 2018 Jan; 19(1):21-35. PubMed ID: 28093662
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
[TBL] [Abstract][Full Text] [Related]
15. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL
Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
[TBL] [Abstract][Full Text] [Related]
16. Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis.
Setyawan J; Hodgkins P; Guérin A; Gauthier G; Cloutier M; Wu EQ; Erder MH
J Med Econ; 2013 Jul; 16(7):962-75. PubMed ID: 23621503
[TBL] [Abstract][Full Text] [Related]
17. [Lisdexamfetamine dimesylate: a Treatment Option for Children and Adolescents with Attention Deficit/Hyperactivity Disorder in Germany and Across Europe].
Häge A; Banaschewski T; Dittmann RW
Fortschr Neurol Psychiatr; 2015 Dec; 83(12):676-85. PubMed ID: 26714249
[TBL] [Abstract][Full Text] [Related]
18. Switch to Lisdexamfetamine in the Treatment of Attention-Deficit Disorder at a Psychiatric Outpatient Clinic for School-Aged Children: A Danish Cohort Study.
Søndergaard NR; Nørøxe KB; Carlsen AH; Randing SH; Warrer P; Thomsen PH; Clausen L
J Child Adolesc Psychopharmacol; 2024 Apr; 34(3):137-147. PubMed ID: 38608011
[No Abstract] [Full Text] [Related]
19. The efficacy and safety profile of lisdexamfetamine dimesylate, a prodrug of d-amphetamine, for the treatment of attention-deficit/hyperactivity disorder in children and adults.
Najib J
Clin Ther; 2009 Jan; 31(1):142-76. PubMed ID: 19243715
[TBL] [Abstract][Full Text] [Related]
20. The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders.
Roncero C; Álvarez FJ
Expert Rev Neurother; 2014 Aug; 14(8):849-65. PubMed ID: 24948428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
